| Literature DB >> 35681244 |
Arce Domingo-Relloso1,2,3, Angela L Riffo-Campos4,5, Martha Powers6, Maria Tellez-Plaza7, Karin Haack8, Robert H Brown9, Jason G Umans10,11, M Daniele Fallin12, Shelley A Cole8, Ana Navas-Acien13, Tiffany R Sanchez13.
Abstract
BACKGROUND: Epigenetic modifications, including DNA methylation (DNAm), are often related to environmental exposures, and are increasingly recognized as key processes in the pathogenesis of chronic lung disease. American Indian communities have a high burden of lung disease compared to the national average. The objective of this study was to investigate the association of DNAm and lung function in the Strong Heart Study (SHS). We conducted a cross-sectional study of American Indian adults, 45-74 years of age who participated in the SHS. DNAm was measured using the Illumina Infinium Human MethylationEPIC platform at baseline (1989-1991). Lung function was measured via spirometry, including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), at visit 2 (1993-1995). Airflow limitation was defined as FEV1 < 70% predicted and FEV1/FVC < 0.7, restriction was defined as FEV1/FVC > 0.7 and FVC < 80% predicted, and normal spirometry was defined as FEV1/FVC > 0.7, FEV1 > 70% predicted, FVC > 80% predicted. We used elastic-net models to select relevant CpGs for lung function and spirometry-defined lung disease. We also conducted bioinformatic analyses to evaluate the biological plausibility of the findings.Entities:
Keywords: American Indians; DNA methylation; Epigenetics; Lung disease; Lung function
Mesh:
Year: 2022 PMID: 35681244 PMCID: PMC9185990 DOI: 10.1186/s13148-022-01294-8
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 7.259
Fig. 1Flowchart of included participants. *5 participants missing education data, 2 smoking status, 11 BMI, 52 LDL cholesterol, 14 hypertension treatment, 111 eGFR, 30 diabetes
Participant characteristics
| Overall ( | Airflow limitation ( | Restriction ( | Non-cases ( | |
|---|---|---|---|---|
| Female, % | 61 | 51 | 70 | 62 |
| Age (years), median (IQR) | 55 (49, 61) | 59 (52, 65) | 56 (49, 61) | 53 (48, 60) |
| Height (cm), median (IQR) | 165 (159, 173) | 168 (160, 176) | 163 (158, 169) | 165 (160, 173) |
| BMI, median (IQR) | 29.7 (26.3, 33.8) | 27.7 (24.3, 31.5) | 31.5 (27.3, 35.7) | 29.9 (26.8, 33.8) |
| Smoking, | ||||
| Never | 32 | 26 | 37 | 32 |
| Former | 30 | 26 | 28 | 32 |
| Current | 38 | 48 | 35 | 36 |
| Center, % | ||||
| Arizona | 14 | 7 | 27 | 14 |
| North Dakota and South Dakota | 43 | 29 | 47 | 46 |
| Oklahoma | 43 | 63 | 27 | 40 |
| eGFR, median (IQR) | 100.7 (92.1, 107.5) | 97.7 (88.3, 105.2) | 101.7 (93.4, 107.9) | 101.1 (93.1, 108.0) |
| Education (years), median (IQR) | 12 (10, 14) | 11 (9, 13) | 12 (9, 13) | 12 (10, 14) |
| Prior TB diagnosis, % | 13 | 18 | 15 | 12 |
| FEV1 (L), median (IQR) | 2.5 (2.0, 3.0) | 2.1 (1.6, 2.7) | 1.9 (1.6, 2.2) | 2.7 (2.3, 3.2) |
| FVC (L), median (IQR) | 3.3 (2.7, 4.0) | 3.4 (2.7, 4.4) | 2.3 (1.9, 2.8) | 3.4 (2.9, 4.1) |
| FEV1/FVC, median (IQR) | 76.5 (71.1, 75.3) | 65.2 (59.2, 68.2) | 80.3 (75.7, 85.9) | 77.8 (74.8, 81.4) |
IQR Interquartile range, eGFR Estimated glomerular filtration rate, TB Tuberculosis, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity
Fig. 2Venn diagram of elastic-net selected DMPs for lung function outcomes, airflow limitation, and restrictive pattern
Top five differentially methylated positions for continuous lung function measures (FEV1, FVC, and FEV1/FVC)
| CpG | Chr | Gene | Function | Mean difference (95% CI) | |
|---|---|---|---|---|---|
| cg25325512 | 6 | Serine/Threonine-Protein Kinase Pim-1. Cell proliferation and survival | 0.22 (0.15, 0.29) | 2.91E−09 | |
| cg26058502 | 1 | Regulation of cell growth and lipid metabolism | 0.18 (0.11, 0.25) | 2.79E−07 | |
| cg01641754 | 5 | Uncharacterized | 0.18 (0.11, 0.24) | 3.46E−07 | |
| cg15167811 | 9 | Regulator of cell differentiation | 0.16 (0.1, 0.23) | 4.85E−07 | |
| cg07941411 | 3 | T-cell proliferation and cytokine production | − 0.15 (− 0.21, − 0.09) | 2.00E−06 | |
| cg02203833 | 7 | Serine/threonine kinase. Synaptic plasticity and neuronal migration | 0.21 (0.12, 0.30) | 4.00E−06 | |
| cg19265480 | 1 | Associated with developmental and neurogenetic diseases | − 0.19 (− 0.27, − 0.11) | 3.00E−06 | |
| cg18140268 | 1 | Associated with developmental and neurogenetic diseases | − 0.18 (− 0.26, − 0.11) | 5.00E−06 | |
| cg07343418 | 12 | Brain development, synaptic plasticity | − 0.19 (− 0.26, − 0.11) | 2.00E−06 | |
| cg03725414 | 16 | Promotes matrix assembly | 0.18 (0.10, 0.26) | 1.30E−05 | |
| cg25001882 | 14 | Cell adhesion in the nervous system, synaptic plasticity | 33.0 (21.3, 44.6) | 3.32E−08 | |
| cg16771344 | 9 | Tyrosine receptor kinase. Phosphorylates itself and members of the MAPK signaling pathway | 29.9 (18.5, 41.2) | 2.99E−07 | |
| cg12420787 | 2 | Calcium channel. Plasticity on the brain | 21.7 (13.4, 30.1) | 3.84E−07 | |
| cg03636183 | 19 | Blood coagulation, inflammation and response to pain. Associated with smoking and lung cancer | 18.1 (11.0, 25.2) | 5.80E−07 | |
| cg27127773 | 16 | Repair of specific types of DNA lesions | − 42.6 (− 59.2, − 25.9) | 6.17E−07 | |
Top five DMPs selected by elastic-net models. Mean differences reported from linear models comparing percentile 90 vs percentile 10 of DNA methylation. Models were adjusted for age, squared age, height, prior tuberculosis diagnosis, sex, BMI, smoking status (never, former, current), cumulative smoking (pack-years), study center (Arizona, Oklahoma, or North and South Dakota), cell counts (CD8T, CD4T, NK, B cells and monocytes) and five genetic PCs
Top five differentially methylated positions for airflow limitation and restrictive pattern lung function
| CpG | Chr | Gene | Function | Odds Ratio (95% CI) | |
|---|---|---|---|---|---|
| cg20304857 | 2 | Catalyze transfer of N-acetyl-D-galactosamin to hydroxyl groups on serines and threonines | 2.8 (1.9, 4.3) | E−06 | |
| cg07842459 | 1 | Homophilic adhesion molecule | 2.8 (1.8, 4.3) | 2E−06 | |
| cg17916980 | 16 | Serine/Threonine-Protein Phosphatase. Dephosphorylates AKT family kinase | 2.5 (1.7, 3.7) | 2E−06 | |
| cg03647068 | 2 | Morphogenesis, cytokinesis, cell polarity | 3.0 (1.9, 4.8) | 2E−06 | |
| cg06100532 | 16 | Involved in the maturation of specific proteins in the endoplasmic reticulum | 2.8 (1.8, 4.3) | 3E−06 | |
| cg05504535 | 10 | Regulatory role in RNA editing | 0.3 (0.2, 0.5) | 1.86E−07 | |
| cg04890495 | 11 | Cell adhesion, cohesion of the endothelial monolayer at intercellular junctions in vascular tissue | 0.3 (0.2, 0.5) | 5.92E−07 | |
| cg03320255 | 19 | Transcriptional repressor | 0.3 (0.2, 0.5) | 8.72E−07 | |
| cg20024687 | 8 | Role in the modification of DNA topology | 0.4 (0.2, 0.5) | 3.00E−06 | |
| cg19693031 | 1 | Protects cells from oxidative stress | 0.4 (0.3, 0.6) | 4.00E−06 | |
Top five DMPs selected by elastic-net models. Odds Ratios reported from regression models comparing percentile 90 vs percentile 10 of DNA methylation. Models were adjusted for age, squared age, prior tuberculosis diagnosis, sex, BMI, smoking status (never, former, current), cumulative smoking (pack-years), study center (Arizona, Oklahoma, or North and South Dakota), cell counts (CD8T, CD4T, NK, B cells and monocytes) and five genetic PCs
Fig. 3Workflow for protein–protein interaction networks
Fig. 4Top enriched traits for FEV1, FVC, FEV1/FVC, airflow limitation and restrictive pattern from the EWAS Toolkit
Effect estimates and p values of the CpGs identified in the meta-analysis by Imboden et al. that were replicated in the SHS
| CpG | Chr | Gene | Lung function endpoint in meta-analysis | Coefficient (SE) in meta-analysis | Lung function endpoint in the SHS | Coefficient of the elastic-net model in the SHS | |
|---|---|---|---|---|---|---|---|
| cg05575921 | 5 | FEV1; FVC; FEV1/FVC | 0.78 (0.057); 0.37 (0.064); 0.12 (0.008) | 1.48E−43; 8.79E−09; 7.22E−50 | FEV1/FVC | 1.10 | |
| cg03636183 | 19 | FEV1; FVC; FEV1/FVC | 1.27 (0.098); 0.62 (0.11); 0.20 (0.015) | 4.08E−39; 2.04E−08; 4.5E−43 | FEV1/FVC | 1.13 | |
| cg21566642 | 2 | FEV1; FEV1/FVC | 0.94 (0.074); 0.15 (0.011) | 7.43E−37; 5.02E−43 | FEV1/FVC | 0.21 | |
| cg03329539 | 2 | FEV1; FEV1/FVC | 1.61 (0.15); 0.26 (0.023) | 1.46E−26; 5.58E−30 | FEV1/FVC | 0.76 | |
| cg24859433 | 6 | FEV1/FVC | 0.30 (0.034) | 2.05E−19 | FEV1 | 0.019 | |
| cg19859270 | 3 | FEV1; FEV1/FVC | 2.74 (0.36); 0.47 (0.06) | 1.34E−14; 2.8E−18 | FEV1/FVC | 2.46 | |
| cg18181703 | 17 | FEV1 | 1.19 (0.16) | 3.74E−14 | FEV1; FVC | 0.093; 0.034 | |
| cg01127300 | 22 | FEV1 | 0.85 (0.12) | 1.19E−12 | FEV1/FVC | 0.057 | |
| cg06826457 | 12 | FEV1 | 1.12 (0.18) | 5.35E−10 | Airflow limitation; FEV1/FVC | − 0.028; 0.13 |